FierceBiotechOriginal article
{"a":[{"_":"Alumis crushed by midstage lupus flop but plots path to phase 3 for TYK2 inhibitor","$":{"href":"/biotech/alumis-crushed-midstage-lupus-flop-plots-path-phase-3-tyk2-inhibitor","hreflang":"en"}}]}
Phase 2negativeenvudeucitinibNegative
AI Analysis
Summary
Alumis' envudeucitinib failed to meet primary and secondary endpoints in a phase 2b lupus trial, but the company intends to advance the TYK2 inhibitor into phase 3 based on efficacy signals observed in a prespecified patient subgroup.
Clinical Trial Data
Phase
2b
Primary Endpoint
Not Met
Outcome Details
Missed primary and secondary endpoints in phase 2b trial; however, company plans to advance to phase 3 based on efficacy evidence in prespecified patient subgroup
Importance:6/10
Sentiment:
-0.60
Phase 2 failureTYK2 inhibitorlupussubgroup analysisphase 3 planned
Related Companies
Read the original article
Published by FierceBiotech on September 1, 2026 9:28 AM